In an 8 to 1 vote, the Oncologic Drug Advisory Committee determined that findings from the phase 3 STARGLO trial are not applicable to patients in the US with diffuse large B-cell lymphoma.

In the last year, there has been excitement about the use of MRD in multiple myeloma trials and new approaches to assessing ...

Prof Martin Dreyling discusses the shifting treatment landscape for patients with difficult-to-treat mantle cell lymphoma.

In arm 1 of the trial, the dose-escalation portion, patients will receive mRNA-4106 at a test dose as monotherapy. In arm 2, ...

In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with relapsed/refractory multiple myeloma and the use of chimeric antigen receptor ...

Melphalan/hepatic delivery system showed better survival and response rates than best alternative care in metastatic uveal ...

During a Community Case Forum event, Antoinette R. Tan, MD, MHS, discussed the DESTINY-Breast04 and DESTINY-Breast06 trials ...

Paul B. Renz, DO, discussed the ideal uses of MR-LINAC in pancreatic, prostate, liver, head and neck, and rectal cancers.

Samuraciclib improved progression-free survival in HR+ advanced breast cancer patients without TP53 mutations or liver ...

The FDA has approved new agents in ovarian cancer and non–small cell lung cancer and paved the way for novel antibody-drug conjugate developments.

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...

During a live event, Xiuning Le, MD, PhD, discussed clinical trials of supportive care for infusion reaction and skin rash ...